Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2026—Cybersecurity and image management are key concerns for laboratories adopting digital pathology and AI. While cloud-based systems offer enhanced security and scalability, onboarding new vendors and instruments remains challenging due to stringent security requirements and potential vulnerabilities.
February 2026—CAP TODAY publisher Bob McGonnagle spoke on Dec. 2, 2025 with Steve Swartzell and Scott Johnston of ELITechGroup. McGonnagle’s questions and their answers follow. A few of the questions came from the roundtable audience and are identified as such.
Bob McGonnagle: Steve, how long have you been with ELITech and what is your background in molecular diagnostics?
Steve Swartzell: I am director of customer experience and have been with ELITechGroup for 22 years. My background is in microbiology. I started as a research scientist in R&D and I was an application specialist working directly with customers. I have many years of lab experience as well. Now I oversee all the field activities for ELITechGroup MDx in the U.S. Continue reading …
Watch the full conversation:
This roundtable discussion is sponsored by ELITechGroup.
January 2026—Michigan Medicine implemented two biomarkers, GFAP and UCH-L1, to evaluate traumatic brain injury in the emergency department, aiming to reduce unnecessary CT scans. A retrospective study showed high sensitivity for the markers, but limitations were identified, such as their ineffectiveness for …
January 2026—Despite significant advancements in algorithm development, implementing AI in clinical practice faces a bottleneck. The challenge lies in operationalizing these algorithms within existing clinical workflows, requiring infrastructure, reimbursement structures, and validation frameworks.
January 2026—Cytokine panels are crucial for managing post-CAR T-cell therapy toxicities like CRS, ICANS, and IEC-HS. These panels help identify specific cytokine elevations, guiding the use of targeted cytokine-blocking agents.
January 2026—The 2025 CAP accreditation checklists include new requirements for humidity, specimen self-collection, body fluid crystal analysis, and pneumatic tube transport of blood specimens.
January 2026—The Association for Diagnostics and Laboratory Medicine released new guidance discouraging clot-based testing in patients receiving direct oral anticoagulants (DOACs).
Bringing next-generation sequencing (NGS) in-house can be approached in two ways: a rapid, comprehensive implementation or a gradual, progressive build. Florida Cancer Specialists opted for a rapid approach, starting with a complex pancancer solid tumor panel, which facilitated the addition of smaller assays.
The CAP Artificial Intelligence Committee is developing a guide for laboratories on implementing AI, covering the entire machine learning life cycle. While laboratories can begin using AI now, they must ensure full validation, even for FDA-approved tools, due to potential biases and population drift.
The absence of CDC surveillance data due to the government shutdown has created uncertainty about the severity and impact of the current respiratory virus season. While regional public health surveillance provides some insights, concerns remain about the potential for a severe season, exacerbated by vaccine hesitancy and changes in vaccine guidance.
